The researchers loaded the platform with two pairs of drugs approved by the FDA: BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma ...

Companies are currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer types. Although proof-of-concept for ...

or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management of gliomas are ongoing, it cannot be excluded, in case of ...

BRAF, and PIK3CA that drive CVM pathogenesis. These discoveries have opened avenues for targeted therapies, including MEK inhibitors and mTOR inhibitors, promising effective alternatives to ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

The combination of Hsp90 inhibitors with RAF or MEK inhibitors may achieve a better pathway inhibition in RAS and/or BRAF mutant tumors. This work will contribute significantly toward better patient ...

Drawing upon these findings, other researchers suggested that combining BRAF inhibitors with another treatment type known as MEK inhibitors could improve outcomes compared to selective BRAF inhibitors ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

BRAF, and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors ...